Full Press Release Details
Rhythm Pharmaceuticals Announces FDA Approval of IMCIVREE setmelanotide for Patients as Young as 2 Years Old.
RYTM
Rhythm Pharmaceuticals Announces FDA Approval of IMCIVREE setmelanotide for Patients as Young as 2 Years Old
Key Takeaway: Rhythm Pharmaceuticals Announces FDA Approval of IMCIVREE setmelanotide for Patients as Young as 2 Years Old